Autoimmune gastrointestinal dysmotility: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
Line 45: Line 45:
[[Category:Digestive diseases]]
[[Category:Digestive diseases]]
[[Category:Autoimmune diseases]]
[[Category:Autoimmune diseases]]
{{dictionary-stub1}}
<gallery>
File:Image1.jpg|Image of a healthy digestive tract
File:Image2.jpg|Diagram showing gastrointestinal dysmotility
File:Image3.jpg|Symptoms of autoimmune gastrointestinal dysmotility
File:Image4.jpg|Treatment options for gastrointestinal dysmotility
File:Image5.jpg|Dietary recommendations for managing dysmotility
</gallery>

Revision as of 14:26, 10 March 2025

[[File:|250px|alt=|]]
Synonyms N/A
Pronounce
Field N/A
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis
Prevention
Treatment
Medication
Prognosis
Frequency
Deaths


Autoimmune gastrointestinal dysmotility (AGID) is an autoimmune disease autonomic neuropathy affecting the gastrointestinal organs and digestive system of the body. Dysmotility is when the strength or coordination of the esophagus, stomach or intestines muscles do not work as they should.<ref>Bolen, Barbara Bradley. "Dysmotility". About.com. Retrieved 14 January 2013.</ref>

Presentation

Associated illnesses

Often AGID is a symptom of other problems, including colon cancer, lupus, lung, breast, or ovarian carcinoma or thymoma. or other diseases. Irritable bowel syndrome (IBS) is the most recognized form of AGID gastrointestinal dysmotility citation needed (December 2014) .

Diagnosis

AGID is diagnosed with a complete medical history, exam of patients motility and with special blood tests looking for autoantibodies consistent with neurologic autoimmunity.<ref>,

 Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal Dysmotility, 
 Clinical Gastroenterology and Hepatology, 
 2008,
 Vol. 6(Issue: 9),
 pp. 988–92,
 DOI: 10.1016/j.cgh.2008.04.009,
 PMID: 18599359,
 PMC: 2741093,</ref> Blood tests included evaluations of immunofluorescence (neuronal nuclear and cytoplasmic antibodies), radioimmunoprecipitation assays (neuronal and muscle plasma membrane cation channel antibodies), and enzyme-linked immunosorbent assay (muscle striational antibodies). A finding, along with medical history, of ganglionic neuronal acetylcholine receptor and N-type voltage-gated calcium channel autoantibodies in the blood stream would result in a medically acceptable diagnosis of AGID.<ref name="ncbi">, 
 Autoimmune Gastrointestinal Dysmotility Treated Successfully with Pyridostigmine, 
 Gastroenterology, 
 2006,
 Vol. 131(Issue: 5),
 pp. 1592–6,
 DOI: 10.1053/j.gastro.2006.06.018,
 PMID: 17101331,</ref>

Treatment

Medications to relieve nausea and vomiting or to enhance mobility may be helpful, as may cholinesterase inhibitors. Immunotherapy and plasma exchange have also been reportedly effective.<ref>

Autoimmune gastrointestinal dysmotility | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program(link). rarediseases.info.nih.gov.


Accessed 2018-04-17.


</ref> Pyridostigmine is a pharmaceutical treatment option for patients with AGID.<ref name="ncbi" /> In severe cases patients with AGID are required to abandon eating foods, requiring them to get nourishment through a process called parenteral nutrition, where the patient is fed via a permanent IV and the liquid nourishment is infused directly in the blood stream, as opposed to a feeding tube.

References

<references group="" responsive="1"></references>


Further reading